Articles

• All
• CVD
• CKD
• Dialysis
• SGLT2i
• Hypertension
• Hyperglycaemia
• AKI
• RAAS
• Anaemia
• Transplantation

• 

  Dapagliflozin after cardiac surgery: reducing AKI or reducing the diagnosis of AKI?

  1 Sep 2026

  • AKI
  • CVD
  • SGLT2i
  • Editorial

• 

  Dapagliflozin and acute kidney injury after cardiac surgery

  31 Aug 2026

  • AKI
  • CVD
  • SGLT2i

• 

  Proteomic insights into dapagliflozin in CKD

  30 Aug 2026

  • CKD
  • SGLT2i

• 

  UKKW news: Debate – population screening for CKD in those aged over 50 years

  12 Mar 2026

  • CKD
  • RAAS
  • SGLT2i

• 

  Growing CONFIDENCE in co-prescribing of SGLT2 inhibitors and non-steroidal MRAs

  7 Jul 2025

  • SGLT2i
  • CKD
  • Hypertension
  • Editorial

• 

  Combination finerenone and empagliflozin in CKD with diabetes

  6 Jul 2025

  • CKD
  • SGLT2i
  • Hypertension

• 

  SOUL: effects of oral semaglutide and cardiovascular outcomes independent of SGLT2 inhibitor use

  17 May 2025

  • CKD
  • CVD
  • SGLT2i

• 

  SGLT2i kidney outcome trial participants vs a real-world population

  11 May 2024

  • SGLT2i
  • CKD
  • Hyperglycaemia

• 

  SGLT2 inhibitors versus GLP-1 receptor agonists for renal patients: does it matter?

  14 Mar 2024

  • SGLT2i
  • Hyperglycaemia
  • Editorial